> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letters
- URL: https://www.fdaweb.com/latest-fda-warning-letters-4/
- Published: 2019-11-26T12:00:00.000Z
- Updated: 2026-09-14T15:54:26.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145593

FDA has posted its latest batch of Warning Letters. They can be accessed by clicking on the link following each letter.

**EPH Technologies**, Silver Spring, MD (11/18): After reviewing company-operated Web sites, FDA determined that its Detoxoplex, Sinoplex and Migrenza products are unapproved new drugs. For example, Detoxoplex is being promoted for treating opioid withdrawal symptoms, but the product has not been determined by FDA to be safe and effective for such use. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eph-technologies-inc-590707-11182019?ref=fdaweb.com).

**Lohxa**, Worcester, MA (9/10): FDA inspected Lohxa in March and cited significant GMP violations for finished pharmaceuticals. For example, the company failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates. It also failed to clean, maintain, and sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of drug products. And, the company failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lohxa-llc-581785-09102019?ref=fdaweb.com).